Equities analysts forecast that CymaBay Therapeutics Inc (NASDAQ:CBAY) will report earnings per share (EPS) of ($0.36) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for CymaBay Therapeutics’ earnings. The highest EPS estimate is ($0.34) and the lowest is ($0.41). CymaBay Therapeutics posted earnings of ($0.30) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 20%. The firm is scheduled to announce its next earnings report on Thursday, August 8th.
According to Zacks, analysts expect that CymaBay Therapeutics will report full-year earnings of ($1.48) per share for the current fiscal year, with EPS estimates ranging from ($1.75) to ($1.36). For the next year, analysts anticipate that the firm will post earnings of ($1.58) per share, with EPS estimates ranging from ($2.05) to ($0.91). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that that provide coverage for CymaBay Therapeutics.
CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.03).
Several large investors have recently made changes to their positions in CBAY. Fosun International Ltd lifted its holdings in CymaBay Therapeutics by 70.8% in the 4th quarter. Fosun International Ltd now owns 792,096 shares of the biopharmaceutical company’s stock worth $6,199,000 after purchasing an additional 328,289 shares in the last quarter. MetLife Investment Advisors LLC lifted its holdings in CymaBay Therapeutics by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 43,720 shares of the biopharmaceutical company’s stock worth $484,000 after purchasing an additional 15,542 shares in the last quarter. Raymond James & Associates lifted its holdings in CymaBay Therapeutics by 7.7% in the 4th quarter. Raymond James & Associates now owns 82,205 shares of the biopharmaceutical company’s stock worth $647,000 after purchasing an additional 5,899 shares in the last quarter. Bailard Inc. purchased a new position in CymaBay Therapeutics in the 4th quarter worth approximately $984,000. Finally, LPL Financial LLC purchased a new position in CymaBay Therapeutics in the 3rd quarter worth approximately $282,000. Institutional investors own 88.57% of the company’s stock.
Shares of NASDAQ:CBAY opened at $12.30 on Friday. The company has a market cap of $866.23 million, a P/E ratio of -9.76 and a beta of 1.77. The company has a quick ratio of 18.66, a current ratio of 18.66 and a debt-to-equity ratio of 0.01. CymaBay Therapeutics has a 12-month low of $6.31 and a 12-month high of $15.00.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
See Also: Return On Assets
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.